Grundläggande statistik
| CIK | 1674988 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zealand Pharma A/S. - ADR
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 30, 2022 |
Company announcement 32/2022 dated August 8, 2022 Exhibit 99.1 Company announcement ? No. 32/ 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market ? Zealand will consolidate trading to Nasdaq Copenhagen, the company?s primary and most liquid stock exchange ? Decision is part of Zealand?s refocused strategy to prioritize R&D and streamline corporate operations Copenhagen, D |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15F CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38178 Zealan |
|
| September 20, 2022 |
As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. |
|
| September 20, 2022 |
As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38178 Zealand Pharma A/S The Nasdaq Global Select Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Sydm |
|
| September 7, 2022 |
Company announcement – No. 38 / 2022 Exhibit 99.1 Company announcement ? No. 38 / 2022 Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE? (dasiglucagon) ? Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to high-single to low-double digit royalties on worldwide net sales ? Zealand wil |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 7, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| August 31, 2022 |
Exhibit 99.1 Company announcement ? No. 37 / 2022 Total number of shares and voting rights in Zealand Pharma at August 31, 2022 Copenhagen, DK and Boston, MA, August 31, 2022 ? Zealand Pharma A/S (?Zealand?) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 31, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 26, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive office |
|
| August 26, 2022 |
Exhibit 99.1 COMPANY ANNOUNCEMENT ? NO. 36 / 2022 Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer Copenhagen, DK and Boston, MA, August 24, 2022 ? Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zeala |
|
| August 10, 2022 |
Company announcement – No. 32/ 2022 Exhibit 99.1 (a) Company announcement – No. 32/ 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market ● Zealand will consolidate trading to Nasdaq Copenhagen, the company’s primary and most liquid stock exchange ● Decision is part of Zealand’s refocused strategy to prioritize R&D and streamline corporate operations Copenhage |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| August 10, 2022 |
Exhibit 99.1 (b) Updated notice to holders of ADSs regarding termination of Deposit Agreement NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS (“ADRs”) REPRESENTING DEPOSITED ORDINARY SHARES OF: ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARE CUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814 Company announcement – No. 33 / 2022 Copenhagen, |
|
| June 2, 2022 |
Exhibit 99.1 Company announcement ? No. 23/ 2022 Company announcement ? No. 23 / 2022 Zealand Pharma launches long-term incentive program for Zealand?s Corporate Management and employees for 2022 Copenhagen, DK and Boston, MA, May 25, 2022 ? Zealand Pharma A/S (?Zealand?) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of inno |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 26, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 ZEALAND PHARMA A/S (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price Per Share(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(3) Equity Ordinary Shares, DKK 1 nominal value per share(4) Zealand Pharma A/S ? 2022 Restricted Stock Unit Plan for Employees in the United States 457 (h) 99,420 $ 12. |
|
| May 26, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 26, 2022 |
Articles of Association of Zealand Pharma A/S, as currently in effect Exhibit 4.1 VEDT?GTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S 2 VEDT?GTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn 1.1 Selskabets navn er Zealand Pharma A/S. Name The Company's name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company's secondary name is Zealand Pharm |
|
| May 26, 2022 |
Zealand Pharma A/S – 2022 Restricted Stock Unit Plan for Board of Directors EXHIBIT 10.2 Acceptance of Restricted Stock Units Award STRICTLY CONFIDENTIAL Submit Deadline Status Award Status N/A 20-April-2022 17:00 (UTC+01:00) Pending Active Congratulations! You are hereby invited to participate in Zealand?s 2022 RSU plan for Board of Directors, and receive an Award of Restricted Stock Units, subject to the terms and conditions as set out below in the Award Agreement. Awar |
|
| May 26, 2022 |
Zealand Pharma A/S – 2022 Restricted Stock Unit Plan for Employees in the United States Exhibit 10.1 Acceptance of Restricted Stock Units Award Submit Deadline Status Award Status N/A 08-June-2022 17:00 (UTC+01:00) Pending Active Congratulations! You are hereby invited to participate in Zealand?s 2022 RSU plan for employees in the United States, and receive an Award of Restricted Stock Units, subject to the terms and conditions as set out below in the Award Agreement. Award Details V |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 25, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 24, 2022 |
Exhibit 99.1 Company announcement ? No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) ? Dasiglucagon met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) w |
|
| May 20, 2022 |
Company announcement – No. 21 / 2022 Exhibit 99.1 Company announcement ? No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go? Insulin Delivery Device ? Deal includes $10 million USD upfront payment to Zealand and sales-based milestones ? Certain inventory related to V-Go? and employees also included under the terms of the deal ? Agreement is part of Zealand?s refocused strategy to seek p |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 16, 2022 |
Exhibit 99.1 Company announcement No. 18 / 2022 Interim report for Q1 2022 Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development Copenhagen, DK and Boston, MA, U.S. May 12, 2022 ? Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 13, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| April 22, 2022 |
Exhibit 99.1 Company announcement ? No. 14 / 2022 Zealand Pharma launches long-term incentive program for Zealand?s Board of Directors for 2022 Copenhagen, DK and Boston, MA, US., April 20, 2022 ? Zealand Pharma A/S (?Zealand?) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces a sha |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 22, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| April 5, 2022 |
Consent of independent registered public accounting firm Exhibit 15.5 ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-230654 on Form F-3 and 333-259997 on Form S-8 of our report dated March 13, 2020, relating to the financial statements of Zealand Pharma A/S, appearing in this Annual Report on Form 20-F/A for the year ended December 31, 2021. ? Copenhagen, April 5 |
|
| April 5, 2022 |
EXHIBIT 4.1 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? Set forth below is a summary of certain information concerning our share capital, as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to, and descrip |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 5, 2022 |
EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, certify that: 1. I have reviewed this annual report on Form 20-F/A of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| April 5, 2022 |
Consent of independent registered public accounting firm EX-15.4 9 zeal-20211231xex15d4.htm EXHIBIT 15.4 Exhibit 15.4 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements (Form F-3 No. 333-230654 and Form S-8 No. 333-259997) of Zealand Pharma A/S of our reports dated March 24, 2022, with respect to the consolidated financial statements of Zealand Pharma A/S, and the effectiv |
|
| April 5, 2022 |
EX-4.7 4 zeal-20211231xex4d7.htm EXHIBIT 4.7 Execution Version Exhibit 4.7 NOTE PURCHASE AGREEMENT dated as of December 13, 2021 among ZEALAND PHARMA US, INC. as Issuer, ZEALAND PHARMA A/S as Parent, THE OTHER OBLIGORS PARTY HERETO, THE PURCHASERS PARTY HERETO, and ZOOLANDER SA LLC as Purchaser Agent TABLE OF CONTENTS Page ARTICLE I ACCOUNTING AND OTHER TERMS 1 ARTICLE II NOTES; TERMS OF PAYMENT; |
|
| April 5, 2022 |
EX-1.1 2 zeal-20211231xex1.htm EXHIBIT 1.1 Exhibit 1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S 22-4068-1 C2.25 P572 2 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn 1.1 Selskabets navn er Zealand Pharma A/S. Name The Company's name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Phar |
|
| April 5, 2022 |
EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, certify that: 1. I have reviewed this annual report on Form 20-F/A of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| April 5, 2022 |
EXHIBIT 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F/A of the |
|
| April 5, 2022 |
EXHIBIT 13.2 PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F/ |
|
| March 30, 2022 |
Exhibit 99.1 Company announcement ? No. 10 / 2022 Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations ? Dr. Adam Steensberg assumes the position of Chief Executive Office refocusing Zealand to better leverage its next-generation peptide platform to address unmet medical needs of patients ? Commercial operations res |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 30, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 25, 2022 |
EXHIBIT 4.1 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? Set forth below is a summary of certain information concerning our share capital, as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to, and descrip |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 25, 2022 |
EXHIBIT 13.2 PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F |
|
| March 25, 2022 |
EXHIBIT 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F of the Co |
|
| March 25, 2022 |
Consent of independent registered public accounting firm EX-15.4 9 zeal-20211231xex15d4.htm EXHIBIT15.4 Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements (Form F-3 No. 333-230654 and Form S-8 No. 333-259997) of Zealand Pharma A/S of our reports dated March 24, 2022, with respect to the consolidated financial statements of Zealand Pharma A/S, and the effective |
|
| March 25, 2022 |
Consent of independent registered public accounting firm EX-15.5 10 zeal-20211231xex15d5.htm EXHIBIT-15.5 Exhibit 15.5 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-230654 on Form F-3 and 333-259997 on Form S-8 of our report dated March 13, 2020, relating to the financial statements of Zealand Pharma A/S, appearing in this Annual Report on Form 20-F for the year e |
|
| March 25, 2022 |
EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 25, 2022 |
Execution Version ? Exhibit 4.7 ? NOTE PURCHASE AGREEMENT dated as of December 13, 2021 among ZEALAND PHARMA US, INC. as Issuer, ZEALAND PHARMA A/S as Parent, THE OTHER OBLIGORS PARTY HERETO, ? THE PURCHASERS PARTY HERETO, and ZOOLANDER SA LLC as Purchaser Agent ? ? ? ? ? TABLE OF CONTENTS ? ? ? ? ? Page ARTICLE I ACCOUNTING AND OTHER TERMS ? 1 ? ? ? ? ? ARTICLE II NOTES; TERMS OF PAYMENT; REVENUE |
|
| March 25, 2022 |
EX-1.1 2 zeal-20211231xex1d1.htm EXHIBIT 1.1 Exhibit 1.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S 22-4068-1 C2.25 P572 2 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn 1.1 Selskabets navn er Zealand Pharma A/S. Name The Company's name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand |
|
| March 25, 2022 |
EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 22, 2022 |
Exhibit 99.1 Focused on Growing our Most Valuable Asset Zealand Pharma Annual Report 2021 Company reg. no. 20045078 Today Annual General Meeting 2021 #WithZeal Contents CEO Letter ? R ead more on page 5 Other supplementary reports 2021 ? Corporate Social Responsibility Report ? R emuneration Report ? Corporate Governance Report See our pipeline ? R ead more on page 19 Overview Zealand Pharma in sh |
|
| March 22, 2022 |
6-K 1 tm224068d36k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 22, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Addres |
|
| March 15, 2022 |
Exhibit 99.1 Company announcement ? No. 9/ 2022 Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. Full Year Results for 2021 Copenhagen, March 10, 2022 ? Zealand Pharma A/S (?Zealand?) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 11, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 10, 2022 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 14, 2022 |
Exhibit 99.1 Company announcement ? No. 8/ 2022 Zealand convenes its Annual General Meeting 2022 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, April 6 2022 at 3:00 pm (CEST) In accordance with Article 11.1 of the Compa |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene |
|
| February 14, 2022 |
ZEAL / Zealand Pharma A/S / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment SC 13G/A 1 tm226155d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Zealand Pharma A/S (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) K9898X127 (CUSIP Number) December 31, 2 |
|
| December 15, 2021 |
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Exhibit 99.1 Company announcement ? No. 75/ 2021 Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital ? Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note ? The non-dilutive debt facility will support continued development of clinical pipeline, including additional indications for dasiglucagon and glepag |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 15, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 22, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offi |
|
| November 22, 2021 |
Exhibit 99.1 Company announcement ? No. 70/ 2021 Company announcement ? No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Company announcement ? No. 70 / 2021 ? Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosing in humans ? Effects on several biomarkers suggest that clinically relev |
|
| November 19, 2021 |
EX-99.1 2 tm2133517d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 69/ 2021 Company announcement – No. 69 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. November 19, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 19, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| November 12, 2021 |
EX-99.1 2 tm2132088d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 67/ 2021 Interim report for 9M 2021 Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies Copenhagen, DK and Boston, MA, U.S. November 11, 2021 – Zealand Phar |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 5, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offic |
|
| November 5, 2021 |
6-K 1 tm2132088d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 5, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Add |
|
| November 5, 2021 |
Exhibit 99.1 Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI) · Agreement grants Zealand a worldwide, exclusive license to use DEKA’s continuous infusion pump for the potential treatment of CHI with dasigluca |
|
| October 4, 2021 |
Zealand Pharma A/S – 2021 Performance Share Unit Plan for Corporate Management (Market-Based PSUs) Exhibit 10.10 Performance Stock Unit Award Acceptance, Market-based PSUs Submit Deadline Status Grant Status Congratulations! You are hereby invited to participate in Zealand?s 2021 PSU plan for Corporate Management, and receive an Award of market-based Performance Stock Units, subject to the terms and conditions as set out below in the Award Agreement. Award Details Recipient Name Award Type Awar |
|
| October 4, 2021 |
Zealand Pharma A/S – 2020 Restricted Share Unit Program EX-10.6 9 tm2128845d1ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Zealand Pharma A/S Restricted share unit PROGRAM 2020 TABLE OF CONTENTS 1 PURPOSE 3 2 ALLOTMENT OF RSUs 3 3 VESTING Period 3 4 ORDINARY DELIVERY OF SHARES BASED ON RSUs 4 5 EXTRAORDINARY VESTING AND DELIVERY OF SHARES BASED ON RSUs CONSIDERED VESTED 4 6 TRANSFER OF EMPLOYMENT 4 7 NO INSIDER TRADING 4 |
|
| October 4, 2021 |
Zealand Pharma A/S – 2020 Agreements on Warrants for Employees Exhibit 10.4 STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Agreement on Warrants ? U.S. Between Zealand Pharma A/S Sydmarken 11 DK-2860 S?borg Denmark and [Name] (the "Warrant Holder") TABLE OF CONTENTS 1 Purpose 3 2 Grant of Warrants 3 3 Vesting of Warrants 3 4 Exercise of the Warrants 4 5 Transfer of shares 4 6 Transferability of Warrants to another party 4 7 Buy Back of Warrants - cash settlement 4 8 |
|
| October 4, 2021 |
Zealand Pharma A/S – 2019 Agreements on Warrants for Management Exhibit 10.2 STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Agreement on Warrants Between Zealand Pharma A/S Smedeland 36 DK-2600 Glostrup Denmark and [Name] [Address] [Address] (the "Warrant Holder") TABLE OF CONTENTS 1 Purpose 3 2 Grant of Warrants 3 3 Ordinary Exercise of the Warrants 3 4 Extraordinary Exercise of the Warrants 4 5 Practicalities in connection with Exercise of the Warrants 5 6 Subscrip |
|
| October 4, 2021 |
Zealand Pharma A/S – 2021 Agreements on Restricted Share Units for Directors Exhibit 10.7 STRICTLY CONFIDENTIAL Agreement on restricted share unitS Between?????? Zealand Pharma A/S Sydmarken 11 DK-2860 S?borg Denmark and?????????????? [Name] [Address] (the "Participant") TABLE OF CONTENTS 1 Purpose 3 2 grant of rsus 3 3 Vesting of RSUs 3 4 ordinary delivery of shares 3 5 EXTRAORDINARY VESTING AND DELIVERY OF SHARES BASED ON RSUs CONSIDERED VESTEd 4 6 termination of office |
|
| October 4, 2021 |
EX-10.11 14 tm2128845d1ex10-11.htm EXHIBIT 10.11 Exhibit 10.11 Performance Stock Unit Award Acceptance, Operational PSUs Submit Deadline Status Grant Status Congratulations! You are hereby invited to participate in Zealand’s 2021 PSU plan for Corporate Management, and receive an Award of operational Performance Stock Units, subject to the terms and conditions as set out below in the Award Agreemen |
|
| October 4, 2021 |
Zealand Pharma A/S – 2020 Agreements on Warrants for Management EX-10.5 8 tm2128845d1ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Agreement on Warrants – U.S. Between Zealand Pharma A/S Sydmarken 11 DK-2860 Søborg Denmark and Frank Sanders (the "Warrant Holder") TABLE OF CONTENTS 1 Purpose 3 2 Grant of Warrants 3 3 Vesting of Warrants 3 4 Exercise of the Warrants 4 5 value Cap for each grant 4 6 Transfer of shares 4 7 Transferab |
|
| October 4, 2021 |
Articles of Association of Zealand Pharma A/S, as currently in effect EX-4.1 2 tm2128845d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 VEDTÆGTER ARTICLES OF ASSOCIATION zealand pharma a/s zealand pharma a/s VEDTÆGTER ARTICLES OF ASSOCIATION zealand pharma a/s (CVR-nr.: 20 04 50 78) zealand pharma a/s (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company's name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The C |
|
| October 4, 2021 |
Zealand Pharma A/S – 2021 Restricted Stock Unit Plan for Corporate Management EX-10.9 12 tm2128845d1ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 Acceptance of Restricted Stock Units Award Submit Deadline Status Award Status N/A 05-Jun-2021 17:00 (UTC+01:00) Pending Active Congratulations! You are hereby invited to participate in Zealand’s 2021 RSU plan for Corporate Management, and receive an Award of Restricted Stock Units, subject to the terms and conditions as set out below in t |
|
| October 4, 2021 |
As filed with the Securities and Exchange Commission on October 1, 2021 As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. |
|
| October 4, 2021 |
Zealand Pharma A/S – 2019 Long Term Incentive Plan (Performance Share Units) Exhibit 10.3 Between Zealand Pharma A/S Smedeland 36 DK-2600 Glostrup Denmark and Marino Garcia SVP, Corporate & Business Development 40 East 21 Street, Apt6 10010 NY, NY (the "Warrant Holder") STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE AGREEMENT ON WARRANTS 2 TABLE OF CONTENTS 1 PURPOSE .................................................................................................................. |
|
| October 4, 2021 |
Zealand Pharma A/S – 2018 Agreements on Warrants for Management EX-10.1 4 tm2128845d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Agreement on Warrants Between Zealand Pharma A/S Smedeland 36 DK-2600 Glostrup Denmark and [Name] [Address] [Address] (the "Warrant Holder") TABLE OF CONTENTS 1 Purpose 3 2 Grant of Warrants 3 3 Ordinary Exercise of the Warrants 3 4 Extraordinary Exercise of the Warrants 4 5 Practicalities in connecti |
|
| October 4, 2021 |
Zealand Pharma A/S – 2021 Restricted Stock Unit Plan for Employees EX-10.8 11 tm2128845d1ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 Acceptance Of Restricted Stock Units Award Submit Deadline Status Award Status N/A 05-Jun-2021 17:00 (UTC+01:00) Pending Active Congratulations! You are hereby invited to participate in Zealand’s 2021 RSU plan for employees in the United States, and receive an Award of Restricted Stock Units, subject to the terms and conditions as set out |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2021 Commission File Number: 001-38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal ex |
|
| October 1, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information of Zealand Pharma A/S (?Zealand?) is presented to illustrate the estimated effects of the acquisition of substantially all of the medical technology business from Valeritas Holdings, Inc. (?Valeritas?) consummated on April 2, 2020 (the ?Acquisition?). |
|
| September 7, 2021 |
EX-99.1 2 tm2124962d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 56 / 2021 New Employee Elected Director to the board of Zealand Pharma A/S Copenhagen, DK and Boston, MA, U.S. September 1, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078). Anneline Nansen has been instated as an employee elected member of the Board of Directors of Zealand effective as of 1 |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 6, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offi |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 26, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| August 26, 2021 |
Company announcement – No. 53 / 2021 Exhibit 99.1 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Your publication date and time will appear here. | Source: Zealand PharmaCompany announcement ? No. 53 / 2021Zealand Pharma increases its share capital as a consequence of exercise of employee warrantsCopenhagen, DK and Boston, MA, U.S. August 20, 2021 ? Zealand Pharma A/S (Nasdaq: ZEAL) (CVR- |
|
| August 13, 2021 |
EX-99.1A 2 tm2124962d1ex99-1a.htm EXHIBIT 99.1A Exhibit 99.1a Company announcement – No. 50 / 2021 Interim report for H1 2021 Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas Copenhagen, DK and Boston, MA, U.S. August 12, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the dis |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 13, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| August 13, 2021 |
First Half 2021 Report Zealand Pharma 12 August 2021 EX-99.1B 3 tm2124962d1ex99-1b.htm EXHIBIT 99.1B Exhibit 99.1b First Half 2021 Report Zealand Pharma 12 August 2021 1H 2021 presentation 12 August 2021 2 Forward looking statement This presentation contains “forward - looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma’s expectations or forecasts of future eve |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 30, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| July 30, 2021 |
EX-99.1 2 tm2122793d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 47 / 2021 Zealand Pharma A/S – Final Transactions Under Share Repurchase Program Copenhagen, DK, 27 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the E |
|
| July 21, 2021 |
6-K 1 tm2122793d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 21, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Addres |
|
| July 21, 2021 |
EX-99.1 2 tm2122793d199-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 46 / 2021 Zealand Pharma A/S – Transaction Under Share Repurchase Program Copenhagen 12 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parlia |
|
| July 21, 2021 |
6-K 1 tm2122793d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 21, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Addres |
|
| July 21, 2021 |
EX-99.1 2 tm2122793d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 47 / 2021 Zealand Pharma A/S – Transaction Under Share Repurchase Program Copenhagen, DK and Boston, MA, 20 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 |
|
| July 12, 2021 |
Exhibit 99.1 Company announcement ? No. 45 / 2021 Zealand Zealand Pharma A/S ? Transaction Under Share Repurchase Program Copenhagen 6 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (M |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 12, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 29, 2021 |
EX-99.1 2 tm2120867d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 42 / 2021 Zealand Pharma - Share Buy-Back Program Under Safe Harbour to Aquire Danish Common Stock for Employee Incentive Programs ZEALAND PHARMA A/S - SHARE BUY-BACK PROGRAM UNDER SAFE HARBOUR TO AQUIRE DANISH COMMON STOCK FOR EMPLOYEE INCENTIVE PROGRAMS On 29 June 2021, Zealand Pharma A/S ("Zealand") will initia |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 28, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 28, 2021 |
EX-99.1 2 tm2120867d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 43 / 2021 Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA) Zealand Pharma to Present Data on Glepaglutide at the 17 Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA) · Company to present thre |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 24, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 25, 2021 |
EX-99.1 2 tm2118790d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 41 / 2021 Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection · ZEGALOGUE now available in both an auto-injector and prefilled syringe for the treatment of severe hypoglycemia in pa |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 4, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 4, 2021 |
EX-99.1 2 tm2118790d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 35 / 2021 Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH · FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscore |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 27, 2021 |
Exhibit 99.1 Company announcement ? No. 33 / 2021 Zealand Pharma launches long-term incentive program for Zealand?s US based Corporate Management for 2021 Copenhagen, DK and Boston, MA, U.S., May 27, 2021 ? Zealand Pharma A/S (?Zealand?) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, a |
|
| May 17, 2021 |
6-K 1 tm2116714d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 17, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address |
|
| May 17, 2021 |
EX-99.1 2 tm2116714d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 30 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, May 14, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand's shar |
|
| May 12, 2021 |
Exhibit 99.1 Company announcement ? No. 29 / 2021 Interim report for Q1 2021 Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue? (dasiglucagon) injection Financial results for the first quarter of 2021 ? Revenue: DKK 47.8 million / USD 7.5 million (DKK 12.4 million / USD 1.8 million in the first three months of 2020). ? Net operating expenses: DKK -284.8 million / USD |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 12, 2021 |
EX-99.1 2 tm2116130d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zealand Pharma launches long-term incentive program for Zealand’s Executive Management and employees for 2021Company announcement – No. 28/ 2021Zealand Pharma launches long-term incentive program for Zealand’s Executive Management and employees for 2021Copenhagen, DK and Boston, MA, U.S. May 5, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR- |
|
| May 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2115017d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address |
|
| May 4, 2021 |
EX-99.1 2 tm2115017d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26/ 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated pers |
|
| May 4, 2021 |
Company announcement – No. 25 / 2021 EX-99.1 2 tm2115017d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 25 / 2021 Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes Copenhagen, DK and Boston, MA, U.S., May 3, 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focuse |
|
| May 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) I |
|
| April 29, 2021 |
Exhibit 99.1 Company announcement – No. 23 / 2021 Copenhagen, April 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), announces the implementation of a new share-based long-term incentive program for Zealand’s Board of Directors in accordance with Zealand's Remuneration Policy as adopted at the annual general meeting held on April 15, 2021. Accordingly, Zealand has gr |
|
| April 29, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| April 15, 2021 |
EX-99.1 2 tm2113122d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 22 / 2021 Zealand Pharma's Annual General Meeting 2021 Copenhagen, April 15, 2021 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2021 completely electronically. At the meeting, all proposals presented to the General Meeting were adopted. The General |
|
| April 15, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 15, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| April 13, 2021 |
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity EX-99.1 2 tm2112876d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 21 / 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity · New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH. · The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weig |
|
| April 13, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 13, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 26, 2021 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 26, 2021 |
Principal Executive Officer certification pursuant to 18 U.S.C. section 1350 EXHIBIT 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F of the Co |
|
| March 26, 2021 |
Exhibit 4.1 ASSET PURCHASE AGREEMENT Dated as of February 9, 2020 By and Among Zealand Pharma A/S as Purchaser, and VALERITAS, INC. as Seller and VALERITAS HOLDINGS, INC. as Company Affiliates Table of Contents Page Article I. PURCHASE AND SALE OF THE PURCHASED ASSETS; ASSUMPTION OF ASSUMED LIABILITIES 2 1.1 Purchase and Sale of the Purchased Assets 2 1.2 Excluded Assets 4 1.3 Assumption of Liabil |
|
| March 26, 2021 |
Certification of the Financial Officer EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 26, 2021 |
Letter of Deloitte Statsautoriseret Revisionspartnerselskab EX-16.1 8 tm218254-7exh16x1.htm EXHIBIT 16.1 Exhibit 16.1 March 18, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 USA Dear Sirs/Madams: We have read Item 16F of Form 20-F of Zealand Pharma A/S for the year ended December 31, 2020 to be filed on or around March 18, 2021 and have the following comments: 1. We agree with the statements made in the second, thir |
|
| March 26, 2021 |
Principal Financial Officer certification pursuant to 18 U.S.C. section 1350 ? EXHIBIT 13.2? PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. ? 1350, as adopted pursuant to ? 906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20 |
|
| March 26, 2021 |
Certification of the principal Executive Officer ? EXHIBIT 12.1? CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| March 26, 2021 |
Description of Securities registered under Section 12 of the Securities Act of 1933, as amended. EX-2.1 2 tm218254-7exh2x1.htm EXHIBIT 2.1 EXHIBIT 2.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is a summary of certain information concerning our share capital, as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary inclu |
|
| March 23, 2021 |
Zealand Pharma Announces FDA Approval of Zegalogue EX-99.1 2 tm2110589d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes · Zegalogue will be available in both an auto injector and a prefilled syringe for the treatment of severe hypoglycemia in patients with diabetes age 6 or older · |
|
| March 23, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 23, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 19, 2021 |
Letter of Deloitte Statsautoriseret Revisionspartnerselskab EX-16.1 8 tm218254-5exh16x1.htm EXHIBIT 16.1 Exhibit 16.1 March 18, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 USA Dear Sirs/Madams: We have read Item 16F of Form 20-F of Zealand Pharma A/S for the year ended December 31, 2020 to be filed on or around March 18, 2021 and have the following comments: 1. We agree with the statements made in the second, thir |
|
| March 19, 2021 |
Principal Executive Officer certification pursuant to 18 U.S.C. section 1350 ? EXHIBIT 13.1? PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ?1350, as adopted pursuant to ?906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F of the |
|
| March 19, 2021 |
EX-4.1 3 tm218254d6ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 ASSET PURCHASE AGREEMENT Dated as of February 9, 2020 By and Among Zealand Pharma A/S as Purchaser, and VALERITAS, INC. as Seller and VALERITAS HOLDINGS, INC. as Company Affiliates Table of Contents Page Article I. PURCHASE AND SALE OF THE PURCHASED ASSETS; ASSUMPTION OF ASSUMED LIABILITIES 2 1.1 Purchase and Sale of the Purchased Assets 2 1.2 E |
|
| March 19, 2021 |
Certification of the principal Executive Officer EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 19, 2021 |
Principal Financial Officer certification pursuant to 18 U.S.C. section 1350 EXHIBIT 13.2 PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F |
|
| March 19, 2021 |
Certification of the Financial Officer EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 19, 2021 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 19, 2021 |
Description of Securities registered under Section 12 of the Securities Act of 1933, as amended. ? EXHIBIT 2.1? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is a summary of certain information concerning our share capital, as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to, and descript |
|
| March 18, 2021 |
Principal Financial Officer certification pursuant to 18 U.S.C. section 1350 ? EXHIBIT 13.2? PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. ? 1350, as adopted pursuant to ? 906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20 |
|
| March 18, 2021 |
Letter of Deloitte Statsautoriseret Revisionspartnerselskab Exhibit 16.1 March 17, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 USA Dear Sirs/Madams: We have read Item 16F of Form 20-F of Zealand Pharma A/S for the year ended December 31, 2020 to be filed on or around March 17, 2021 and have the following comments: 1. We agree with the statements made in the second, third, fourth and fifth paragraphs of Item 16F fo |
|
| March 18, 2021 |
Consent of independent registered public accounting firm Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-230654) of Zealand Pharma A/S of our reports dated March 17, 2021, with respect to the consolidated financial statements of Zealand Pharma A/S, and the effectiveness of internal control over financial reporting of Zealand Pharma A/S, inc |
|
| March 18, 2021 |
Certification of the Financial Officer ? EXHIBIT 12.2? CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Dallas, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| March 18, 2021 |
EX-4.1 3 tm218254d4ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 ASSET PURCHASE AGREEMENT Dated as of February 9, 2020 By and Among Zealand Pharma A/S as Purchaser, and VALERITAS, INC. as Seller and VALERITAS HOLDINGS, INC. as Company Affiliates Table of Contents Page Article I. PURCHASE AND SALE OF THE PURCHASED ASSETS; ASSUMPTION OF ASSUMED LIABILITIES 2 1.1 Purchase and Sale of the Purchased Assets 2 1.2 E |
|
| March 18, 2021 |
Description of Securities registered under Section 12 of the Securities Act of 1933, as amended. ? EXHIBIT 2.1? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is a summary of certain information concerning our share capital, as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to, and descript |
|
| March 18, 2021 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 18, 2021 |
Consent of independent registered public accounting firm Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements Nos. 333-230654 on Form F-3 of our report dated March 13, 2020, relating to the financial statements of Zealand Pharma A/S, appearing in this Annual Report on Form 20-F for the year ended December 31, 2020. Copenhagen, March 17, 2021 Deloitte Statsautorisere |
|
| March 18, 2021 |
Principal Executive Officer certification pursuant to 18 U.S.C. section 1350 EXHIBIT 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes- Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on Form 20-F of the Co |
|
| March 18, 2021 |
Certification of the principal Executive Officer EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Emmanuel Dulac, certify that: 1. I have reviewed this annual report on Form 20-F of Zealand Pharma A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s |
|
| March 16, 2021 |
EX-99.1 2 tm219947d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company Announcement – No. 13 / 2021 Zealand Pharma convenes its Annual General Meeting 2021 Copenhagen, 16 March, 2021 – Zealand Pharma A/S (the "Company") convenes the Annual General Meeting of the Company to be held on Thursday April 15, 2021 at 3:00 pm (CEST) In accordance with Article 11.1 of the Company's Articles of Association the An |
|
| March 16, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 16, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 12, 2021 |
Annual Report 2020, furnished to the SEC on Form 6-K, dated March 12, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 12, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 12, 2021 |
EX-99.1 2 tm218254d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Growing as a leader in peptide therapeutics Company reg. no. 20045078 Zealand Pharma Annual Report 2020 About Zealand Pharma We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other rare disease areas with significant unmet medical needs 2 Zealand Pharma ∞ Annual Report 2020 Overview 4 Z |
|
| March 11, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-38178 Zealand Pharma A/S (Translation of registrant?s name into English) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive off |
|
| March 11, 2021 |
Full Year 2020 Report Zealand Pharma 11 March 2021 EX-99.2 3 tm219179d2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Full Year 2020 Report Zealand Pharma 11 March 2021 Forward - looking statements • This presentation contains information pertaining to Zealand Pharma A/S (“Zealand”). Neither Zealand nor its management, dire cto rs, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any |
|
| March 11, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 11, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| March 11, 2021 |
EX-99.1 3 tm219179d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VALERITAS HOLDINGS, INC. Consolidated Financial Statements December 31, 2019 and 2018 VALERITAS HOLDINGS, INC. CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2019 AND 2018 Independent Auditors’ Report 1-2 Consolidated Balance Sheets as of December 31, 2019 and 2018 3 Consolidated Statements of Operations for the years ended December 31, 2019 |
|
| March 11, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.3 5 tm219179d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information of Zealand Pharma A/S (“Zealand”) is presented to illustrate the estimated effects of the acquisition of substantially all of the medical technology business from Valeritas Holdings, Inc. (“Valeritas”) consu |
|
| March 11, 2021 |
EX-99.2 4 tm219179d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 VALERITAS HOLDINGS, INC. Condensed Consolidated Financial Statements Unaudited VALERITAS HOLDINGS, INC. (Debtor-In-Possession) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 1 Condensed Consolidated Statements of Operations for the three months ended Ma |
|
| March 11, 2021 |
EX-99.1 2 tm219179d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 12 / 2021 Zealand Pharma: on Track for Potential First Product Launch and Establishing Commercial Operations in the United States Full Year Results for 2020 Copenhagen, March 11, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and developm |
|
| March 4, 2021 |
EX-99.2 3 tm218732d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 R&D Day Delivering on our commitment to patients March 2021 Welcome 2 ##soft-page## 3 Agenda Forward looking statement This presentation contains information pertaining to Zealand Pharma A/S (“Zealand”). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to |
|
| March 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 4, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| March 4, 2021 |
Company announcement – No. 10 / 2021 Exhibit 99.1 Company announcement – No. 10 / 2021 Zealand Pharma Virtual R&D Day Materials Now Available with Live Q&A Session on March 5, 2021 · Prerecorded materials now available on Zealand’s website Copenhagen, DK and Boston, MA, March 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based me |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Zealand Pharma A/S (Name of Issuer) Common Stock (Title of Class of Securities) K9898X127 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 1, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 1, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offic |
|
| February 1, 2021 |
Company announcement – No. 4 / 2021 Exhibit 99.1 Company announcement – No. 4 / 2021 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN M |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Zealand Pharma A/S (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) K9898X127 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing |
|
| January 29, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene |
|
| January 28, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 27, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offic |
|
| January 28, 2021 |
Company announcement – No. 3 / 2021 Exhibit 99.1 Company announcement – No. 3 / 2021 Zealand Pharma announces completion of a directed issue and private placement of approx. 3.6 million new ordinary shares raising gross proceeds of approx. DKK 749 million NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS |
|
| January 27, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm213969d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 27, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Addr |
|
| January 27, 2021 |
Company announcement – No. 2 / 2021 EX-99.1 2 tm213969d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 2 / 2021 Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEM |
|
| January 22, 2021 |
Exhibit 99.1 Company announcement – No.1 / 2021 Zealand Pharma announces update to 2020 financial guidance · Net operating expenses in 2020 are expected to be above the previously guided range of DKK 950-1,000 million by approximately 5-10%. Copenhagen, January 22, 2021 – with reference to the company announcement dated 12 November 2020 (interim report for the period 1 January 2020 to 30 September |
|
| January 22, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Jan 22, 2021 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| December 15, 2020 |
Exhibit 99.1 Company announcement – No. 62 / 2020 Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI) · Dasiglucagon on top of standard of care (SOC) did not significantly reduce the rate of hypoglycemia compared to SOC alone when assessed by intermittent self-measured plasma glucose (primary endpoint) · However, hypoglycemia was reduced |
|
| December 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 15, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offi |
|
| December 11, 2020 |
Exhibit 99.1 Company announcement – No. 60 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, December 11, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by |
|
| December 11, 2020 |
Exhibit 99.1 Company announcement – No. 59 / 2020 Financial calendar for Zealand Pharma in 2021 Copenhagen, December 11, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the following dates for the company's planned financial reporting in 202 |
|
| December 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 11, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| December 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 11, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offi |
|
| November 20, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 20, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| November 20, 2020 |
Exhibit 99.1 Company announcement – No. 55 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, November 20, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by |
|
| November 13, 2020 |
9M 2020 Interim report 12 November 2020 Exhibit 99.2 9M 2020 Interim report 12 November 2020 Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand”). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or any o |
|
| November 13, 2020 |
Exhibit 99.1 Company announcement No. 54 / 2020 Interim report for 9M 2020 Zealand Pharma continues to advance clinical programs and launch capabilities and presents financial results for the first nine months of 2020 Financial results for the first nine months of 2020 ● Revenue: DKK 290.0 million / USD 45.6 million (DKK 29.8 million / USD 4.4 million in the first nine months of 2019). ● Net opera |
|
| November 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 13, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offi |
|
| September 30, 2020 |
Number of shares (nominal value of DKK 1 each) Exhibit 99.1 Company announcement – No. 51 / 2020 Total number of shares and voting rights in Zealand Pharma at September 30, 2020 Copenhagen, September 30, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish St |
|
| September 30, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 30, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive off |
|
| September 22, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2029901d56k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 22, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (A |
|
| September 22, 2020 |
Exhibit 99.1 Company announcement – No. 50 / 2020 Correction: Zealand Pharma announces amendments to its Articles of Association following the granting of warrants Copenhagen, September 22, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announc |
|
| September 22, 2020 |
Exhibit 99.2 Company announcement – No. 50 / 2020 Zealand Pharma announces amendments to its Articles of Association following the granting of warrants Copenhagen, September 18, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that its |
|
| September 16, 2020 |
Exhibit 99.1 Company announcement – No. 49 / 2020 Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program Copenhagen, September 14, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), announces the granting of warrants and restricted share units (RSUs) to employees. The warrants are granted unde |
|
| September 16, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2029901-36k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (A |
|
| September 16, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive off |
|
| September 16, 2020 |
Exhibit 99.1 Company announcement – No. 48 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 11, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by |
|
| September 16, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| September 8, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2029901d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 8, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Ad |
|
| September 8, 2020 |
EX-99.1 2 tm2029901d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press release – No. 47 / 2020 Zealand Pharma builds Global Medical Affairs function with world-renowned experts Dr. Danilo Verge and Dr. David Kendall, both of whom have decades of experience in the global diabetes space, have joined Zealand Pharma. Copenhagen, September 4, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biot |
|
| September 2, 2020 |
Number of shares (nominal value of DKK 1 each) Exhibit 99.1 Company announcement ? No. 45 / 2020 Total number of shares and voting rights in Zealand Pharma at August 31, 2020 Copenhagen, August 31, 2020 ? Zealand Pharma A/S (?Zealand?) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutor |
|
| September 2, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 31, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| August 25, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 21, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive office |
|
| August 25, 2020 |
Exhibit 99.1 Company announcement – No. 44 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, August 21, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a |
|
| August 25, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| August 14, 2020 |
Exhibit 99.1 Company announcement No. 43 / 2020 Interim report for H1 2020 Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application submission for the dasiglucagon HypoPal® rescue pen; pipeline progress including completion of patient enrollment in first Phase 3 trial of dasiglucagon in CHI; and |
|
| August 14, 2020 |
Exhibit 99.2 Interim report for the first half of 2020 Zealand Pharma August 13, 2020 This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or a |
|
| August 14, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 13, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive office |
|
| July 6, 2020 |
Exhibit 99.1 Company announcement – No. 40 / 2020 Zealand Pharma Expands U.S. Operations, Opens New Boston Office · Commercial operations will be headquartered in Boston, as company looks to commercialize pipeline in the U.S. Copenhagen, DK and Boston, MA, U.S. July 6, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company changing lives with innovative peptide-based |
|
| July 6, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 06, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 30, 2020 |
Number of shares (nominal value of DKK 1 each) Exhibit 99.1 Company announcement – No. 39 / 2020 Total number of shares and voting rights in Zealand Pharma at June 30, 2020 Copenhagen, June 30, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Or |
|
| June 30, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 25, 2020 |
Exhibit 99.1 Company announcement – No. 38 / 2020 Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes · The 410-patient Phase 2 trial will compare efficacy of BI 456906 to that of placebo and semaglutide · Dosing of first patient triggers a EUR 20 million milestone payment to Zealand Pharma · The long-acting GLP-1/glucagon |
|
| June 25, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 25, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 25, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 25, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 25, 2020 |
Zealand Pharma major shareholder announcement: Sunstone Life Science Ventures Exhibit 99.1 Company announcement – No. 37 / 2020 Zealand Pharma major shareholder announcement: Sunstone Life Science Ventures Copenhagen, June 23, 2020 – Zealand Pharma A/S ("Zealand") (Nadaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announces the receipt of notification pursuant |
|
| June 22, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 22, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 22, 2020 |
Company announcement – No. 36 / 2020 Exhibit 99.1 Company announcement – No. 36 / 2020 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN |
|
| June 22, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| June 18, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 18, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 18, 2020 |
Company announcement – No. 34 / 2020 Exhibit 99.1 Company announcement – No. 34 / 2020 Zealand Pharma announces directed issues and private placements of up to approx. 2.68 million new ordinary shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN |
|
| June 18, 2020 |
Company announcement – No. 35 / 2020 Exhibit 99.2 Company announcement – No. 35 / 2020 Zealand Pharma announces completion of directed issue and private placement of 2,684,461 new ordinary shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE U |
|
| June 16, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| June 16, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 15, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 16, 2020 |
Exhibit 99.1 Company announcement – No. 32 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, June 12, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a no |
|
| June 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 15, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| June 15, 2020 |
Exhibit 99.1 Company announcement – No. 33 / 2020 Zealand Pharma strengthens executive team with new U.S. leadership Copenhagen, June 15, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank will join Zealand on July 6, 2 |
|
| May 29, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 29, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 29, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 29, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 29, 2020 |
Exhibit 99.4 Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Adam Steensberg 2. Reason for the notification a) Position/status EVP, Chief Medical and Development Officer in Zealand Pharma A/S |
|
| May 29, 2020 |
Exercise of warrants – A. Steensberg EX-99.2 3 tm2021378d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| May 29, 2020 |
Exhibit 99.3 Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Adam Steensberg 2. Reason for the notification a) Position/status EVP, Chief Medical and Development Officer in Zealand Pharma A/S |
|
| May 29, 2020 |
Exhibit 99.1 Company announcement – No. 30 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, May 29, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand's shares or related securities conducted by persons |
|
| May 29, 2020 |
Exhibit 99.1 Company announcement – No. 31 / 2020 Total number of shares and voting rights in Zealand Pharma at May 31, 2020 Copenhagen, May 29, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Orde |
|
| May 27, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| May 27, 2020 |
EX-99.1 3 tm2021072d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 29 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, May 26, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medici |
|
| May 27, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 26, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2020926d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 26, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address |
|
| May 26, 2020 |
Exhibit 99.1 Company Announcement – No. 28 / 2020 Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia • The dasiglucagon HypoPal® rescue pen New Drug Application represents a major milestone in Zealand Pharma’s efforts to bring life changing therapies to people with diabetes • PDUFA target action date schedul |
|
| May 22, 2020 |
Exhibit 99.1 Company announcement – No. 27 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, May 22, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand's shares or related securities conducted by persons |
|
| May 22, 2020 |
Exhibit 99.2 Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Martin Nicklasson 2. Reason for the notification a) Position/status Chairman of the Board of Directors in Zealand Pharma A/S b) Ini |
|
| May 22, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 22, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 15, 2020 |
Interim report for the first quarter of 2020 Zealand Pharma May 14, 2020 Exhibit 99.2 Interim report for the first quarter of 2020 Zealand Pharma May 14, 2020 Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information containe |
|
| May 15, 2020 |
Exhibit 99.1 Company announcement No. 26 / 2020 Interim report for Q1 2020 Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S. commercial operations 1 Interim report for Q1 2020 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR No. 20045078), a biotechnology company changing lives wit |
|
| May 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 15, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 Søborg (Copenhagen) Denmark (Address of principal executive offices) |
|
| May 1, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 30, 2020 Commission File Number: 001 - 38178 Zealand Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Sydmarken 11 2860 S?borg (Copenhagen) Denmark (Address of principal executive offices |
|
| May 1, 2020 |
Exhibit 3.1 VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S ZEALAND PHARMA A/S VEDTÆGTER ARTICLES OF ASSOCIATION ZEALAND PHARMA A/S (CVR-nr.: 20 04 50 78) ZEALAND PHARMA A/S (CVR no.: 20 04 50 78) 1 Navn Name 1.1 Selskabets navn er Zealand Pharma A/S. The Company’s name is Zealand Pharma A/S. 1.2 Selskabets binavn er Zealand Pharmaceuticals A/S. The Company’s secondary name is Zealand Pharmac |
|
| May 1, 2020 |
EX-99.1 3 tm2018214d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Company announcement – No. 24 / 2020 Zealand Pharma announces amendments to its Articles of Association following the granting of warrants Copenhagen, April 29, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced that its Articles of Ass |
|
| April 22, 2020 |
Notifications of exercise of warrants Exhibit 99.2 Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Emmanuel Dulac 2. Reason for the notification a) Position/status President and Chief Executive Officer in Zealand Pharma A/S b) Ini |
